BoMRA alerts on hepatitis reaction from COVID-19 vaccines

The local regulatory watchdog was quick to stress that no cases had been reported in Botswana and encouraged healthcare professionals to be vigilant in identifying and treating any signs of the autoimmune hepatitis.

“Recently, European Medicines Agency’s Pharmacovigilance Risk Assessment Committee identified a safety signal of autoimmune hepatitis which is currently under assessment,” BoMRA said in a statement this week. “According to the report, the signal was detected through assessment of very small number of cases reported after vaccination with mRNA vaccines, Spikevax (Moderna) and Comirnaty (Pfizer).